Valacyclovir hydrochloride - Generic Drug Details

What are the generic drug sources for valacyclovir hydrochloride and what is the scope of freedom to operate?

Valacyclovir hydrochloride is the generic ingredient in two branded drugs marketed by Aiping Pharm Inc, Apotex, Aurobindo Pharma, Chartwell Rx, Cipla, Hetero Labs Ltd V, Hikma, Jubilant Generics, Mylan Pharms Inc, Pharmobedient, Rising, Sun Pharm Inds Ltd, Teva Pharms, Watson Labs Inc, Yiling, Zydus Lifesciences, and Glaxosmithkline, and is included in seventeen NDAs. Additional information is available in the individual branded drug profile pages.

There are twenty-two drug master file entries for valacyclovir hydrochloride. Forty suppliers are listed for this compound.

Summary for valacyclovir hydrochloride

US Patents:	0
Tradenames:	2
Applicants:	17
NDAs:	17
Drug Master File Entries:	22
Finished Product Suppliers / Packagers:	40
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	129
Patent Applications:	3,260
What excipients (inactive ingredients) are in valacyclovir hydrochloride?	valacyclovir hydrochloride excipients list
DailyMed Link:	valacyclovir hydrochloride at DailyMed

Recent Clinical Trials for valacyclovir hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Trogenix ltd	PHASE1
National Taiwan University Hospital	NA
University of Michigan Rogel Cancer Center	PHASE1

See all valacyclovir hydrochloride clinical trials

Pharmacology for valacyclovir hydrochloride

Drug Class	Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor Herpes Zoster Virus Nucleoside Analog DNA Polymerase Inhibitor Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor
Mechanism of Action	DNA Polymerase Inhibitors

US Patents and Regulatory Information for valacyclovir hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Rising	VALACYCLOVIR HYDROCHLORIDE	valacyclovir hydrochloride	TABLET;ORAL	079012-002	May 24, 2010	AB	RX	No	No
Mylan Pharms Inc	VALACYCLOVIR HYDROCHLORIDE	valacyclovir hydrochloride	TABLET;ORAL	078518-002	May 24, 2010	AB	RX	No	No
Glaxosmithkline	VALTREX	valacyclovir hydrochloride	TABLET;ORAL	020487-002	Jun 23, 1995	AB	RX	Yes	Yes

Expired US Patents for valacyclovir hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Glaxosmithkline	VALTREX	valacyclovir hydrochloride	TABLET;ORAL	020487-002	Jun 23, 1995	4,567,182
Glaxosmithkline	VALTREX	valacyclovir hydrochloride	TABLET;ORAL	020487-001	Jun 23, 1995	4,957,924*PED
Glaxosmithkline	VALTREX	valacyclovir hydrochloride	TABLET;ORAL	020487-001	Jun 23, 1995	6,107,302*PED

Market Dynamics and Financial Trajectory for Valacyclovir Hydrochloride

Last updated: February 19, 2026

Valacyclovir hydrochloride, marketed under brand names including Valtrex, primarily treats herpes virus infections such as herpes zoster, genital herpes, and cold sores. The drug's market growth hinges on infection prevalence, pricing strategies, patent status, competitive landscape, and emerging therapies.

Market Overview

Valacyclovir hydrochloride is a prodrug of acyclovir with higher bioavailability, leading to more convenient dosing. The drug’s global sales were approximately USD 1.2 billion in 2022, with a compounded annual growth rate (CAGR) of 4.5% over five years (2018-2022). The market is segmented into North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa, with North America accounting for roughly 45% of global sales.

Key Market Drivers

• High Prevalence of Herpes Infections: Over 500 million people globally have herpes simplex virus (HSV) infections, creating consistent demand. Herpes zoster affects approximately 30 million Americans; the aging population drives further growth.

• Prescribing Trends: Increasing physician awareness, expanded indication approvals, and longer treatment durations contribute to rising prescriptions.

• Generic Entry: Patent expiration in 2014 in the U.S. paved the way for generic versions, reducing prices. Still, branded sales remain dominant due to brand loyalty and physician preference.

• Pricing and Reimbursement: In the U.S., drug reimbursement policies favor branded formulations, supporting higher price points. In Europe, price controls limit revenue growth.

Competitive Landscape

Company	Market Share	Key Products	Patent Status	Notes
GlaxoSmithKline (GSK)	55%	Valtrex (brand)	Patented until 2014	Continues to generate high-margin sales
Mylan, Teva, Sandoz	35%	Generic valacyclovir	Patents expired in 2014	Significant price competition
Others (e.g., Sun Pharma, Hikma)	10%	Generic versions	Post-2014 patent expiry	Focus on price-sensitive markets

The branded drug's revenue remains stable due to brand recognition, while generic entries exert downward pressure on prices.

Regulatory and Patent Landscape

• The original patent for valacyclovir hydrochloride expired in 2014 in the U.S. and Europe, leading to multiple generics.
• GSK maintains supplementary patents on formulation and delivery methods through 2023-2025 in select markets.
• Anti-counterfeiting measures and patent linkage laws limit generic proliferation in some regions.

Future Financial Trajectory

Short-term Outlook (2023-2025)

• Revenue decline: Sales of Valtrex are expected to decline 2-4% annually due to generic competition.
• Market penetration: Generic sales will expand, accounting for roughly 85% of total volume by 2025, but at significantly lower prices.
• Pricing pressure: Average price decrease of 20-30% in the U.S. and Europe expected; price stabilization in emerging markets.

Long-term Outlook (2026-2030)

• Market stabilization: Demand for herpes treatment remains steady due to persistent infection prevalence.
• Emerging therapies: Novel antivirals and vaccines, such as gene editing and immune modulation, may reduce Long-term demand.
• New formulations: Extended-release and combination therapies could provide niche growth opportunities, maintaining premium pricing segments.

Investment Considerations

• R&D pipelines focus on herpes vaccines, which could threaten long-term antiviral demand.
• Geographic expansion in emerging markets could sustain growth, albeit at lower profit margins.
• Licensing opportunities for new formulations and delivery methods could generate additional revenue streams.

Key Challenges

• Price erosion from generics
• Stringent regulatory approval processes for new formulations
• Competition from antiviral drugs with broader indications, such as famciclovir and penciclovir
• Potential impact of new therapeutic modalities, including vaccines

Summary

Valacyclovir hydrochloride’s market remains mature, with revenues declining gradually due to patent expiry and generic competition. Near-term challenges include price pressures and market saturation. Long-term prospects depend on innovation in treatment and prevention strategies.

---

Key Takeaways

• The global market for valacyclovir hydrochloride was approximately USD 1.2 billion in 2022.
• Branded sales comprise roughly 45% of sales; generics account for the rest.
• Sales are declining at 2-4% annually due to patent expiry and fierce price competition.
• Emerging therapies and vaccines threaten future demand; market expansion in emerging regions offers growth potential.
• R&D investments in alternative delivery systems and combination therapies may create niche revenue streams.

---

FAQs

1. What factors influence the decline in valacyclovir hydrochloride’s sales?
The expiration of patents in 2014 enabled generic manufacturers to enter the market, increasing supply and lowering prices, leading to a decline in branded sales.

2. How does generic competition affect pricing?
Price reductions of 20-30% are typical in markets with multiple generics. Branded products can sustain higher prices through brand loyalty, but overall revenue declines.

3. Are there new formulations or delivery methods in development?
Yes. Extended-release formulations and combination drugs are in clinical trials or early development stages to improve adherence and therapeutic outcomes.

4. What is the forecast for the herpesvirus drug market beyond 2025?
Demand for herpes treatments generally remains steady, though the introduction of vaccines and novel antivirals could alter the landscape.

5. Which markets present growth opportunities for valacyclovir hydrochloride?
Emerging markets in Asia and Latin America, where antiviral use is increasing and price sensitivity is lower, offer potential for growth through local manufacturing and tailored pricing strategies.

---

References

[1] IMS Health. (2023). Global Prescription Drug Market Analysis.
[2] GSK Annual Report. (2022). Valacyclovir Revenue and Patent Status.
[3] MarketWatch. (2023). Herpes Drug Market Outlook.
[4] FDA. (2014). Patent Expiry Announcements for Valacyclovir.
[5] Deloitte. (2022). Pharmaceutical Industry Trends and Forecasts.